Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02143518 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity Study of Na-GST-1 With or Without CpG
A Phase 1 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02143518 is a Phase 1 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 24 participants.
The verdict
NCT02143518, a Phase 1 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Na-GST-1 is a protein expressed during the adult stage of the hookworm life cycle that is thought to play a role in the parasite's degradation of host hemoglobin for use as an energy source. Vaccination with recombinant GST-1 has protected dogs and hamsters from infection in challenge studies. This study will evaluate the safety and immunogenicity of two formulations of Na-GST-1 in healthy adult volunteers when co-administered with the immunostimulant CpG 10104, a Toll-like Receptor-9 agonist.
Interventions
- BIOLOGICAL Na-GST-1/Alhydrogel®
- BIOLOGICAL CpG 10104
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02143518
The ClinicalTrials.gov registry entry for NCT02143518 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Na-GST-1/Alhydrogel® is the first listed.
NCT02143518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02143518 about?
NCT02143518 is a clinical study titled "Safety and Immunogenicity Study of Na-GST-1 With or Without CpG". Na-GST-1 is a protein expressed during the adult stage of the hookworm life cycle that is thought to play a role in the parasite's degradation of host hemoglobin for use as an energy source. Vaccination with recombinant GST-1 has protected dogs and hamsters from infection in challenge studies. This ...
What is the current status of trial NCT02143518?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-10. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02143518?
The interventions under investigation include: Na-GST-1/Alhydrogel® (BIOLOGICAL), CpG 10104 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02143518?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.